A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatio
Not Applicable
Completed
- Conditions
- COPD
- Registration Number
- JPRN-UMIN000024905
- Lead Sponsor
- Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Asthma overlap (ACOS); history of lung resection; using inhaled or oral corticosteroid; receiving anti-IgE therapy; and exacerbation of COPD in the 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FEV1 after 4 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Dyspnoea, symptoms, FENO level, and blood eosinophils after 4 weeks of treatment. Adverse events and exacerbation.